ロード中...
Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?
Despite recent advances in the treatment of metastatic castration-resistant prostate cancer (mCRPC), agents that provide durable disease control and long-term survival are still needed. It is a fact that a tumor-induced immunosuppressive status (mediated by aberrant activation of inhibitory immune c...
保存先:
| 出版年: | Oncol Rev |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
PAGEPress Publications, Pavia, Italy
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4943092/ https://ncbi.nlm.nih.gov/pubmed/27471580 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4081/oncol.2016.293 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|